Investor Class Action Filed Against Esperion Therapeutics, Inc. for Securities Fraud Violations
Company Name: Esperion Therapeutics, Inc.
Court: United States District Court for the Eastern District of Michigan
Case Number: 16-cv-10089
Judge: The Hon. Arthur J. Tarnow
Class period: Between August 18, 2015 and September 28, 2015
Security Type: Common Stock

Case Background:

On January 12, 2016, the initial complaint in this securities class action was filed against Esperion Therapeutics, Inc. (“Esperion” or the “Company”) and Esperion’s CEO, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act. Lead Plaintiff alleges that defendants made false and misleading statements by misrepresenting the future prospects for Esperion’s drug ETC-1002. Defendants’ conduct artificially inflated the price of Esperion common stock and operated as a fraud on the Class.

On June 6, 2019, Lead Plaintiff filed a Motion for Class Certification.  That Class was certified by the Court on May 31, 2020.  The Court certified the Class as: all persons who purchased or otherwise acquired the common stock of Esperion Therapeutics, Inc. between August 18, 2015 and September 28, 2015 (inclusive) and were damaged thereby. 

Current Status of Case:

Defendants filed a Motion for Summary Judgement on September 15, 2020. That Motion is currently being briefed by the parties. This action is still ongoing.

If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087 1-844-887-9500 (toll free) or 1-610-667-7706
Or by e-mail at

Please list your purchase and sale transaction(s) in the Esperion Therapeutics, Inc. (NASDAQ: ESPR)  security that is subject of this action between August 18, 2015 and September 28, 2015:

You may also contact James Maro, Jr., Esq. or Adrienne Bell, Esq. at 610.667.7706 or toll free at 844.887.9500, or you may submit your information via email at, or you may click here to print a PDF of this form.

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Esperion Therapeutics, Inc. (2016) prior to the Class Period?
Are you a current or former employee of Esperion Therapeutics, Inc. (2016)?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC
I would like to receive
new case alerts by email